5 results
This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
This study will evaluate the antitumor activity of RAD001 versus placebo in patients with angiomyolipoma associated with either TSC or LAM.
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
This is a research study. The purpose of this study is to test if the investigational medicinal product S48168 (ARM210) is safe and effective when given to patients diagnosed with CPVT1. Primairy objective:To assess the effect of S48168 (ARM210) on…
To study the safety and efficacy of prolonged (>2 hours) end-ischemic DHOPE, by assessing the occurrence of (serious) adverse events during machine perfusion and within 30 days after liver transplantation.